Akums Drugs and Pharmaceuticals Limited has announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026. The company reported a profit of ₹1,145.65 crore for the six-month period. The Board of Directors also approved the financial results and declared a dividend. The results reflect strong operational performance and effective management of resources.
Akums Drugs Announces Q2 FY27 Financial Results
Akums Drugs and Pharmaceuticals Limited has officially released its unaudited standalone financial results for the quarter and half year ending September 30, 2026. The company showcased a robust financial performance, with a profit for the six-month period attributable to the owners of the parent amounting to ₹1,145.65 crore. This demonstrates consistent growth and operational efficiency.
Key Financial Highlights
For the quarter ended September 30, 2026, the company posted a profit of ₹326.37 crore. Total comprehensive income for the six-month period stood at ₹774.76 crore. Revenue from operations for the quarter reached ₹3,950.47 million, contributing to a healthy profit before tax of ₹438.48 million for the period. The company also reported total assets of ₹29,057.92 million as of September 30, 2026.
Dividend Approval and Management Changes
The Board of Directors, following a meeting on November 02, 2026, approved these financial results. Additionally, the Board approved the designation of Mr. Sanjay Kumar as Senior Management Personnel, effective November 02, 2026. The company also confirmed that its initial public offer funds have been fully utilized, with no deviation or variation reported.
Source: BSE
